Effectiveness and safety of «Nifuroxazide-ECO» in therapy of escherichioses in children

In conditions of increasing antibiotic resistance and widespread antibiotic-associated diarrhea caused by Clostridium difficile, it is necessary to choose a rational drug for the empirical treatment of escherichioses, which has a wide range of antibacterial activity and does not lead to the development of serious side effects and disruption of the gut microbiota.

The aim of the study is to assess the effectiveness and safety of the use of the drug “Nifuroxazid-ECO” in the integrated therapy of escherichioses in children.

Patients and methods: 50 patients aged 1 month to 18 years were selected for work by random sampling, hospitalized in the intestinal department of the Pediatric Research and Clinical Center for Infectious Diseases of Russia with non-severe clinical forms of escherichioses. All patients underwent routine clinical, biochemical, instrumental examination. DNA detection of the pathogen was carried out by molecular methods in fecal samples using a set of reagents to detect and differentiate the DNA of diaregenic E. coli in environmental objects and clinical material by polymerase chain reaction (PCR) with hybridization-fluorescent detection. Patients received the drug “Nifuroxazid-ECO”at age dosage, every 6–8 hours for 5–7 days.

Results: Against the background of the therapy, a significant majority of patients showed clinical improvement. The average duration of hospitalization was 4.8 days, the duration of preservation of diarrhoeal syndrome was 3.4 days. The drug showed good tolerability. There were no cases of antibiotic-associated diarrhea, re-hospitalization at an early date after treatment, serious adverse reactions.

Conclusion: Studies have shown that the drug “Nifuroxazid- ECO” is a safe and effective modern drug which can be successfully used in the therapy of non-severe escherichioses in children.

1. Gorelov, A.V. Evolution of escherichioses in children over 25 years / A.V. Gorelov, A.V. Bondareva // E`pidemiologiya i infekczionny`e bolezni. Aktual`ny`e voprosy`. – 2013. – № 5. – S. 46 – 50. (In Russian)

2. Cohen MB, Nataro JP, Bernstein DI, Hawkins J, Roberts N, Staat MA. Prevalence of diarrheagenic Escherichia coli in acute childhood enteritis: a prospective controlled study. The Journal of pediatrics. 2005;146(1):54-61.

3. Libenko, V.N. Clinical and epidemiological features of escherichioses in children at the current stage / V.N. Libenko, A.K. Katarbaev, K.K.Mustafina, M.V. Golovenko // Vestnik Kazakhskogo Naczional`nogo mediczinskogo universiteta. 2016. – № 1. – S. 148 – 151. (In Russian)

4. Lanata CF, Fisher-Walker CL, Olascoaga AC, Torres CX, Aryee MJ, Black RE. Global causes of diarrheal disease mortality in children< 5 years of age: a systematic review. PloS One. 2013;8(9):e72788.

5. Gun`kova, E.V. Features of hemolytic-uremic syndrome in children of various ages / E.V. Gun`kova, I.V.Zorin, A.A. Vyalkova // Pediatr. – 2017. – T.8, № S. – S. M103 – M104. (In Russian)

6. Gonchar, N.V. Escherichioses in children: problems of diagnosis and treatment / N.V. Gonchar, K.D. Ermolenko, O.I. Klimova, E`.A. Martens, Yu.V. Lobzin, S.G. Mardanly` // Medicina e`kstremal`ny`x situacij. – 2020. – T. 22, № 2. – S. 148 – 156. (In Russian)

7. Gorelov, A.V. Starting therapy for escherichioses in children / A.V. Gorelov, A. V. Bondareva // Lechenie i profilaktika. – 2016. – № 4. – S. 69 – 73. (In Russian)

8. Spellberg B., Bartlett J.G., Gilbert D.N. The future of antibiotics and resistance. New England Journal of Medicine. 2013;368(4):299-302.

9. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance – the need for global solutions. The Lancet infectious diseases. 2013;13(12):1057-1098.

10. Roth N, Käsbohrer A, Mayrhofer S, Zitz U., Hofacre C., Domig KJ. The application of antibiotics in broiler production and the resulting antibiotic resistance in Escherichia coli: A global overview. Poultry science. 2019;98(4):1791-1804.

11. Paniagua-Contreras GL, Monroy-Pérez E, Solis RR, Cerón AB, Cortés LRG, Alonso NN, et al. O-serogroups of multi-drug resistant cervicovaginal Escherichia coli harboring a battery of virulence genes. Journal of Infection and Chemotherapy. 2019;25(7):494-497.

12. Jones SE, Versalovic J. Probiotic Lactobacillus reuteri biofilms produce antimicrobial and anti-inflammatory factors. J Clin Invest. 2011;121(6):2242.

13. Sokol H, Pigneur B, Watterlot L, Lakhdari O, BermúdezHumarán LG, Gratadoux JJ, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA. 2008;105(43):16731-16736.

14. Yan F, Cao H, Cover TL, Washington MK, Shi Y, Liu L, et al. Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest. 2011;121(6):2242.

15. Sitnikova, E.A. Study of acute toxicity of nifuroxazide preparations in the form of suspension / E.A. Sitnikova, E.P. Rogozhnikova, S.G. Mardanly`, V.A. Kisseleva // Toksikologicheskij vestnik. – 2019. – T. 154, № 1. – S. 29 – 33. (In Russian)

16. Bagateliya S.A. Aspects of Nifuroxazid diarrhea treatment / S.A. Bagateliya, E.A. Sitnikova, N.D. Vojtenkov // Izvestiya GGTU. – 2020. – Vy`pusk 1. – S. 62 – 64. (In Russian)

17. Butorova, L. Maintaining patients with sharp diarrhea at an out-patient and polyclinic stage / L. Butorova, M. Kalashnikova, N. Krajnikova, M. Osadchuk, T. Plavnik, G. Tokmulina // Vrach. – 2015. – № 10. – S. 78 – 84. (In Russian)

18. Balakin, V.D. Comparative price analysis of outpatient treatment of acute bacterial diarrhea with nifuroxazid suspension drugs / V.D. Balakin, E.A. Sitnikova // Mater. VI Vseross. Nauchno-prakt. konf. «Perspektivy` vnedreniya innovacionny`x texnologij v medicine i farmacii»; GGTU (Orexovo-Zuevo). 2019. – S. 36-39. (In Russian)

19. Gonchar, N.V. Antibiotic and phagoresistency of clinical strains of E. coli in hospitalized children of St. Petersburg with escherichioses / N.V. Gonchar, I.V. Partina, O.I. Ny`rkova, A.S. Drap // Antibiotiki i ximioterapiya. – 2014. – № 9–10. – S. 38 – 43. (In Russian)

20. Gonchar, N.V. Etiological and epidemiological features of combined acute intestinal infections in children / N.V. Gonchar, I.V. Razd`yakonova, N.V. Skripchenko, S.G. Grigor`ev // Zhurnal infektologii. – 2020. – T. 12. – № 2. – S. 113 – 118. (In Russian)